The role of estrogen support during the luteal phase of in vitro fertilization-embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support.
OBJECTIVE
To evaluate the possible role for estrogen supplementation to the P luteal phase support of GnRH agonists (GnRH-a)- and hMG-induced IVF-ET cycles.


METHODS
In vitro fertilization unit in a tertiary care university hospital.


METHODS
A prospectively randomized study.


METHODS
One hundred consecutive patients undergoing ET after IVF were assigned into one of two luteal supplementation regimens.


METHODS
In all patients enrolled in the study, ovulation was induced using the midluteal regimen for pituitary down regulation with GnRH-a followed by follicular stimulation with hMG. The first group received IM P 50 mg/d, as luteal phase support, starting the day of ET. The second group received the same dosage of P, combined with oral E2 valerate, 2 mg/d. Serum levels of P and E2 were monitored every 4 days for 16 days after ET.


METHODS
Pregnancy rates (PRs) and live birth rates per ET.


RESULTS
No significant difference in E2 or P levels throughout the cycle was observed between groups. Similar PRs per ET and the live birth rates were also observed between group A and B (28% versus 26.5% and 78.6% versus 76.1%, respectively).


CONCLUSIONS
No advantage was found in the addition of E2 valerate to P luteal phase support of GnRH-a- and hMG-induced IVF-ET cycles.
Lewin
A
A
Department of Obstetrics and Gynecology, Hadassah University Hospital, Ein-Kerem, Jerusalem, Israel.
Benshushan
A
A
Mezker
E
E
Yanai
N
N
Schenker
J G
JG
Goshen
R
R
D000328:Adult; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008183:Luteal Phase; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000627:therapeutic use*; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000627:therapeutic use
D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol